ULTRAGENYX PHARMACEUTICAL INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2015 | — | $531.1M | $93.6M |
| FY2016 | — | $474.0M | $161.1M |
| FY2017 | — | $383.5M | $100.5M |
| FY2018 | — | $608.9M | $113.4M |
| FY2019 | — | $653.8M | $433.6M |
| FY2020 | — | $1.15B | $713.5M |
| FY2021 | — | $922.6M | $307.6M |
| FY2022 | — | $352.0M | $132.9M |
| FY2023 | — | $275.0M | $214.0M |
| FY2024 | — | $255.0M | $174.0M |